Abstracts tagged "dermatomyositis and myositis"

Abstract Number: 2298 • 2018 ACR/ARHP Annual Meeting
Developing a Classification Criteria for Cutaneous Dermatomyositis Utilizing the Delphi Technique
Josef Concha¹, Victoria P. Werth¹, Joseph F. Merola², David Fiorentino³, Jan Dutz⁴, Manabu Fujimoto⁵, Mark Goodfield⁶, Chia-Chun Ang⁷, Filippa Nyberg⁸ and Beatrix Volc-Platzer⁹, ¹University of Pennsylvania, Philadelphia, PA, ²Clinical Unit for Research Innovation & Trials, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Dermatology, Stanford University School of Medicine, Stanford, CA, ⁴Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada, ⁵University of Tsukuba, Faculty of Medicine, Department of Dermatology, Tsukuba, Japan, ⁶Leeds General Infirmary, Leeds, United Kingdom, ⁷Changi General Hospital, Singapore, Singapore, ⁸Karolinska Institute, Solna, Sweden, ⁹Wiener Krankenanstaltenverbund, Vienna, Austria
Background/Purpose: The new European League Against Rheumatism / American College of Rheumatology (EULAR / ACR) classification criteria for inflammatory myopathies are able to identify patients…
Abstract Number: 849 • 2017 ACR/ARHP Annual Meeting
Tumor TIF1 Mutations and Loss of Heterozygosity Related to Cancer Associated Myositis
Iago Pinal-Fernandez¹, Berta Ferrer-Fabregas², Ernesto Trallero-Araguas¹, Eva Balada¹, Maria Angeles Martinez³, Jose Cesar Milisenda⁴, Gloria Aparicio-Español⁵, Moises Labrador-Horrillo¹, Vicente Garcia-Patos¹, Josep Maria Grau-Junyent⁴ and Albert Selva O'Callaghan⁶, ¹Internal Medicine, Autoimmune Diseases Unit. Vall d´Hebron Hospital, Barcelona, Spain, ²Pathology, Vall d´Hebron, Barcelona, Spain, ³Immunology, Immunology Department, Barcelona, Spain, ⁴Muscle Research Group and Ciberer, Hospital Clinic Provincial, Barcelona, Spain, ⁵Dermatology, Vall d´Hebron Hospital, Barcelona, Spain, ⁶Internal Medicine, Hospital Universitari General Vall d'Hebron, Barcelona, Spain
Background/Purpose: To analyze the influence of genetic alterations and differential expression of the TIF1 genes in the pathophysiology of cancer-associated myositis (CAM). Methods: Whole exome…
Abstract Number: 853 • 2017 ACR/ARHP Annual Meeting
Anti-TIF-1 Antibody Positivity Is Associated with a Five-Fold Increase in Cancer Risk in the Idiopathic Inflammatory Myopathies
Alexander Oldroyd^1,2, Jamie C Sergeant^1,3, Paul New⁴, Neil J. McHugh^5,6, Zoe Betteridge⁵, Janine Lamb⁷, William Ollier⁷, Robert Cooper^4,7,8 and Hector Chinoy^2,9, ¹Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester, United Kingdom, ³Centre for Biostatistics, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁴MRC/ARUK Centre for Integrated Research into Musculoskeletal Ageing, University of Liverpool, Liverpool, United Kingdom, ⁵Department of Pharmacy and Pharmacology, The University of Bath, Bath, United Kingdom, ⁶Royal National Hospital for Rheumatic Diseases, Bath, UK, Bath, United Kingdom, ⁷Division of Population Health, Health Services Research and Primary Care, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁸Department of Rheumatology, Aintree University Hospital, Liverpool, United Kingdom, ⁹Department of Rheumatology, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, United Kingdom
Background/Purpose: There is an increased cancer risk associated with the idiopathic inflammatory myopathies (IIM). Studies have identified that positivity for the autoantibody against transcriptional intermediary…
Abstract Number: 2155 • 2017 ACR/ARHP Annual Meeting
Myositis As a Complication of Checkpoint Blockade at a Comprehensive Cancer Center
Mohsin Shah¹, Jean Tayar¹, Noha Abdel-Wahab^1,2 and Maria Suarez-Almazor¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ²Rheumatology and Rehabilitation Department, Assiut University Hospitals, Assiut, Egypt, Assiut, Egypt
Background/Purpose: Immune checkpoint inhibitor therapy (ICI) has surfaced as a successful and robust treatment option in the fight to end cancer. As we gain more…
Abstract Number: 272 • 2016 ACR/ARHP Annual Meeting
Interferon Chemokine Score and Other Cytokine Measures Predict Changes in Disease Activity in Patients with Juvenile and Adult Dermatomyositis
Cynthia S. Crowson¹, Jeannette M. Olazagasti Lourido², Molly S. Hein³, Richard S. Pendegraft⁴, Michael A. Strausbauch⁵, Timothy B. Niewold⁶, Floranne C. Ernste⁷, Theresa L. Wampler Muskardin³, Erik J. Peterson⁸, Emily C. Gillespie⁹ and Ann M Reed¹⁰, ¹Health Sciences Research, Mayo Clinic, Rochester, MN, ²University of Puerto Rico, San Juan, Puerto Rico, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Biomedical Statistics and informatics, Rochester, MN, ⁵Surgical Research, Mayo Clinic, Rochester, MN, ⁶Rheumatology and Immunology, Mayo Clinic, Rochester, MN, ⁷Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ⁸Center for Immunology/Department of Medicine, University of Minnesota, Minneapolis, MN, ⁹Medicine, University of Minnesota, Minneapolis, MN, ¹⁰Rheumatology, Duke University, Durham, NC
Background/Purpose: Methods: Multiplexed immunoassays (Meso Scale Discovery) enabled simultaneous measurement of IFN-regulated chemokines and other pro- and anti-inflammatory cytokines specific to differentiation of specific…
Abstract Number: 2314 • 2016 ACR/ARHP Annual Meeting
Anti-Mi2 Dermatomyositis Revisited: Pure DM Phenotype with Muscle Fiber Necrosis and High Risk of Malignancy
Océane Landon-Cardinal¹, Grégoire Monseau², Yoland Schoindre³, Aude Rigolet¹, Nicolas Champtiaux¹, Baptiste Hervier¹, Agathe Masseau⁴, Eric Hachulla⁵, Thomas Papo⁶, Benjamin Terrier⁷, Alain Meyer⁸, Jean-Emmanuel Kahn³, François Maurier⁹, Francis Gaches¹⁰, Emmanuelle Salort-Campana¹¹, Thierry Zenone¹², Nathalie Costedoat-Chalumeau⁷, Florian Perez¹³, Maxime Samson¹⁴, Anne-Marie Piette³, Guillaume Moulis¹⁰, Sylvain Audia¹⁵, Séverine Genot¹⁶, Nicolas Schleinitz¹⁷, Guillaume Lefevre⁵, Laurence Verneuil¹⁸, Olivier Benveniste¹⁹, Yves Allenbach¹ and Boris Bienvenu²⁰, ¹Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ²Internal Medicine, Caen University Hospital, Caen, France, ³Internal Medicine, Foch Hospital, Suresnes, France, ⁴Internal Medicine, Nantes University Hospital, Nantes, France, ⁵Internal Medicine, Lille University Hospital, Lille, France, ⁶Bichat University Hospital - Internal Medicine, Paris, France, ⁷Internal Medicine, Cochin University Hospital, Paris, France, ⁸Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁹Internal Medicine, Sainte-Blandine de Metz Hospital, Metz, France, ¹⁰Internal Medicine, Toulouse University Hospital, Toulouse, France, ¹¹Neurology, La Timone University Hospital, Marseille, France, ¹²Internal Medicine, Valence Hospital, Valence, France, ¹³Neurology, Albi Hospital, Albi, France, ¹⁴Dijon University Hospital, Dijon, France, ¹⁵Internal Medicine, Dijon University Hospital, Dijon, France, ¹⁶Internal Medicine, Martigues Hospital, Martigues, France, ¹⁷La Timone University Hospital, Marseille, France, ¹⁸Dermatology, Caen University Hospital, Caen, France, ¹⁹Pitié-Salpêtrière University Hospital, Paris, France, ²⁰Caen University Hospital, Caen, France
Background/Purpose: Anti-Mi2 autoantibodies (Aabs) have been proposed to be highly specific for dermatomyositis (DM) and to be associated with a DM classical phenotype consisting of…
Abstract Number: 2320 • 2016 ACR/ARHP Annual Meeting
Oropharyngeal Dysphagia in Autoimmune Myositis
Jessica Nehme¹, Jean-Paul Makhzoum², Josiane Bourré-Tessier³, Yves Troyanov⁴, Marianne Landry¹, Océane Landon-Cardinal⁵, Marvin J. Fritzler⁶, Anne-Marie Mansour⁷, Eric Rich⁸, Jean-Richard Goulet⁹, Tamara Grodzicky¹⁰, Edith Villeneuve², Frédéric Massicotte¹¹, Florence Weber¹², Martial Koenig¹³, Sylvie Desmarais¹⁴, José Ferreira², Benjamin Ellezam¹⁵, Ira N. Targoff¹⁶ and Jean-Luc Senécal², ¹Université de Montréal, Montreal, QC, Canada, ²Université de Montréal, Montréal, QC, Canada, ³Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ⁴Rheumatology, Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada, ⁵Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ⁶Medicine, University of Calgary, Calgary, AB, Canada, ⁷medicine, Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada, ⁸Div of Rheumatology, C H Univ de Montreal, Montreal, QC, Canada, ⁹246 av Edison, CHUM - H, Saint-Lambert, QC, Canada, ¹⁰Rheumatology, Hôpital Notre-Dame du CHUM, Montreal, QC, Canada, ¹¹Hôpital Notre-Dame, Montr, QC, Canada, ¹²Hôpital St-Luc, Montreal, QC, Canada, ¹³Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, ¹⁴Centre Hospitalier Pierre-Boucher, Longueuil, QC, Canada, ¹⁵Hôpital Ste-Justine, Montreal, QC, Canada, ¹⁶University of Oklahoma, Oklahoma City, OK
Background/Purpose: Oropharyngeal dysphagia (OPD) is an ominous finding in autoimmune myositis (AIM), yet few studies have evaluated the disease subsets at higher risk for this…
Abstract Number: 2213 • 2014 ACR/ARHP Annual Meeting
Gene Expression Profiling of T Helper Subsets in Blood and Affected Muscle Tissues Reveals Differential Activation Pathways in Patients with Juvenile and Adult Dermatomyositis
Consuelo Lopez de Padilla¹, Molly S. Hein¹, Cynthia S. Crowson², Richard S. Pendegraft³, Erik J. Peterson⁴, Emily Baechler⁵ and Ann M. Reed¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Biomedical Statistics and informatics, Rochester, MN, ⁴University of Minnesota, Minneapolis, MN, ⁵Medicine, University of Minnesota, Minneapolis, MN
Background/Purpose: The molecular and cellular basis for juvenile and adult dermatomyositis (JDM and ADM) presumably is similar. However, important differences in the clinical features, outcome…
Abstract Number: 2210 • 2014 ACR/ARHP Annual Meeting
Redefining Dermatomyositis: Description of New Diagnostic Criteria That Differentiate Pure Dermatomyositis from Overlap Myositis with Dermatomyositis Features
Marie-Pier Payette¹, Yves Troyanov¹, Ira N. Targoff², Jean-Pierre Raynauld¹, Suzanne Chartier³, Jean-Richard Goulet¹, Josiane Bourré-Tessier¹, Eric Rich¹, Tamara Grodzicky¹, Marvin J. Fritzler⁴, France Joyal⁵, Martial Koenig⁵ and Jean-Luc Senécal¹, ¹Department of Medicine, Division of Rheumatology, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ²Veterans Affairs Medical Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Division of Dermatology, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ⁴Mitogen Advanced Diagnostics Laboratory, Faculty of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Department of Medicine, Division of Internal Medicine, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada
Background/Purpose: Dermatomyositis (DM) is a major form of autoimmune myositis (AIM). The characteristic DM rash (Gottron's papules, heliotrope rash) and perifascicular atrophy (PFA) at muscle…
Abstract Number: 2086 • 2013 ACR/ARHP Annual Meeting
Defining The Prevalence and Associated Risk Factors For Calcinosis In Adult Dermatomyositis Patients
Jessie Werner¹, Jason Liebowitz², Andrew L. Mammen³ and Lisa Christopher-Stine⁴, ¹Medicine, University of Maryland School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³NIAMS, NIH, Bethesda, MD, ⁴Medicine and Neurology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Calcinosis is known to be associated with junvenile dermatomyositis, but the prevalence and risk factors associated with the development of calcinosis in adult dermatomyositis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].